Toronto Dominion Bank’s XBiotech XBIT Stock Holding History

Toronto Dominion Bank’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2	Closed	–	–	1937
2022 Q1	$0	Hold	2	–	–	﹤0.01%	2046
2021 Q4	$0	Buy	+2	New	+$26	﹤0.01%	2059

Other funds holding XBIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Toronto Dominion Bank's XBIT Position: Q2 2022 in Review

Toronto Dominion Bank sold out of XBiotech (XBIT) in Q2 2022, closing a stake of 2 shares.

Toronto Dominion Bank first reported a position in XBIT in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 56 funds tracked by Wall St. Rank hold XBIT as of Q2 2022.

Toronto Dominion Bank reported no remaining XBiotech position as of Q2 2022 after selling out during the quarter.
Toronto Dominion Bank sold 2 XBiotech shares in Q2 2022.
Toronto Dominion Bank first reported a position in XBiotech in Q4 2021 and held it in 2 quarters.
Toronto Dominion Bank's XBiotech position peaked at $0 in Q1 2022.
56 funds tracked by Wall St. Rank held XBiotech as of Q2 2022.

Based on Toronto Dominion Bank's 13F filing for Q2 2022, filed 11 Aug 2022.